Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report

BACKGROUND: The BRCA2 gene is a well-known tumor suppressor gene implicated in breast and ovarian cancers. BRCA1/2 mutations can be sensitive to poly ADP-ribose polymerase (PARP) inhibitors such as olaparib. However, some of these patients develop resistance to this treatment and an essential factor...

Descripción completa

Detalles Bibliográficos
Autores principales: del Giglio, Auro, da Costa Aguiar Alves, Beatriz, Murad, André Márcio, Fonseca, Fernando Luiz Affonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519093/
https://www.ncbi.nlm.nih.gov/pubmed/37743480
http://dx.doi.org/10.1186/s13256-023-04139-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519093/
https://www.ncbi.nlm.nih.gov/pubmed/37743480
http://dx.doi.org/10.1186/s13256-023-04139-x

Ejemplares similares